Briacell Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Briacell Therapeutics Corp
BCTX Stock  USD 7.25  0.03  0.41%   
Briacell Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Briacell Therapeutics' valuation are provided below:
Market Capitalization
14 M
Earnings Share
(33.87)
We have found one hundred twenty available fundamental signals for Briacell Therapeutics Corp, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Briacell Therapeutics Corp prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 4.7 M in 2026. Enterprise Value is likely to rise to about (6.8 M) in 2026
Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 178.6 K, Interest Expense of 61.9 K or Other Operating Expenses of 45.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.19. Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Briacell Stock
Check out the analysis of Briacell Therapeutics Correlation against competitors.

Briacell Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets35.9 M34.2 M17.6 M
Slightly volatile
Total Current Liabilities6.6 M6.3 M2.4 M
Slightly volatile
Accounts Payable5.5 M5.2 M1.8 M
Slightly volatile
Cash9.9 M16.6 M11.7 M
Slightly volatile
Non Current Assets Total1.3 M2.1 M1.6 M
Pretty Stable
Cash And Short Term Investments29.7 M28.2 M14.4 M
Slightly volatile
Common Stock Shares Outstanding337.7 K486.6 K409.2 K
Pretty Stable
Liabilities And Stockholders Equity35.9 M34.2 M17.6 M
Slightly volatile
Non Current Liabilities Total507.2 K533.9 K7.4 M
Slightly volatile
Other Stockholder Equity156 M148.6 M28.4 M
Slightly volatile
Total Liabilities8.1 M6.8 M9.5 M
Slightly volatile
Total Current Assets33.1 M31.5 M15.8 M
Slightly volatile
Net Receivables937.7 K893 K333.4 K
Slightly volatile
Other Current Liabilities633.2 K1.1 M633.6 K
Slightly volatile
Common Stock168.9 M160.9 M52.7 M
Slightly volatile
Intangible Assets223.2 K291.8 K161.6 K
Slightly volatile
Long Term Investments505.3 K481.3 K107.3 K
Slightly volatile
Short and Long Term Debt Total27.8 K29.2 K573.9 K
Slightly volatile
Common Stock Total Equity79.2 M75.4 M34.9 M
Slightly volatile
Short and Long Term Debt262.4 K276.2 K850.4 K
Slightly volatile
Capital Stock45.8 M83 M32.2 M
Slightly volatile
Short Term Debt213.6 K224.8 K660.3 K
Slightly volatile
Non Current Liabilities Other37.8 M36 M13.6 M
Slightly volatile
Other Liabilities37.8 M36 M11.8 M
Slightly volatile
Long Term Debt22.2 K23.4 K102.1 K
Slightly volatile
Capital Surpluse4.2 M4.7 M5.1 M
Slightly volatile

Briacell Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses45.6 M43.4 M15.1 M
Slightly volatile
Total Operating Expenses45.4 M43.2 M15 M
Slightly volatile
Selling General Administrative7.2 M6.8 M2.5 M
Slightly volatile
Research Development35.6 M33.9 M10.8 M
Slightly volatile
Interest Income186.2 K331.2 K129.3 K
Slightly volatile
Reconciled Depreciation101.3 K96.5 K27.5 K
Slightly volatile
Selling And Marketing Expenses399788547
Pretty Stable

Briacell Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow10.1 M16.6 M11.9 M
Slightly volatile
Stock Based Compensation873.1 K893.4 K823.9 K
Slightly volatile
Depreciation178.6 K170.1 K43 K
Slightly volatile
Issuance Of Capital Stock3.8 M4 M6.8 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Invested Capital622.1 K673.5 K810.7 K
Slightly volatile
Average Payables749.9 K714.2 K740.4 K
Slightly volatile
Capex To Depreciation0.00.0185
Slightly volatile
Payables Turnover0.04390.03750.0699
Slightly volatile
Cash Per Share46.1348.56103
Slightly volatile
Days Payables Outstanding10.7 K10.1 K7.5 K
Slightly volatile
Net Current Asset Value357.4 K402 K438.8 K
Slightly volatile
Income Quality1.430.951.9999
Pretty Stable
Tangible Asset Value628.6 K675.2 K819.2 K
Slightly volatile
Intangibles To Total Assets0.00930.00980.0776
Very volatile
Current Ratio5.475.7614.4631
Very volatile
Capex Per Share0.00.070.0262
Slightly volatile
Average Receivables1 M967.4 K277.2 K
Slightly volatile
Interest Debt Per Share0.130.144.5275
Pretty Stable
Debt To Assets5.0E-45.0E-40.3018
Slightly volatile
Days Of Payables Outstanding10.7 K10.1 K7.5 K
Slightly volatile
Ebt Per Ebit0.830.8865.9697
Very volatile
Long Term Debt To Capitalization4.0E-44.0E-44.0E-4
Slightly volatile
Quick Ratio5.475.7614.4049
Very volatile
Cash Ratio2.883.0311.6802
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.171.6001
Slightly volatile
Debt Ratio5.0E-45.0E-40.3018
Slightly volatile

Briacell Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.7 M4.9 M118.9 M
Pretty Stable
Working Capital357.4 K402 K438.8 K
Slightly volatile

Briacell Fundamental Market Drivers

Briacell Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
12th of June 2024
Next Financial Report
View
31st of January 2024
Next Fiscal Quarter End
View
23rd of October 2024
Next Fiscal Year End
View
31st of October 2023
Last Quarter Report
View
31st of July 2023
Last Financial Announcement
View

About Briacell Therapeutics Financial Statements

Briacell Therapeutics investors use historical fundamental indicators, such as Briacell Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Briacell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-3.8 K-3.6 K
Cost Of Revenue170.1 K178.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft

Additional Tools for Briacell Stock Analysis

When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY